BioPharma Drug Approval
Neobe Therapeutics Raises US$6.8 Million to Advance Engineered Bacteria for Solid Tumours
Neobe has secured a seed round of US$6.8 million (£5 million) to accelerate the development of engineered bacteria that break down the physical...
November 11, 2026 | News
Pierre Fabre and XtalPi Partner on AI-Driven Oncology Drug Discovery
Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) are pleased to announce an agreement under which they will collaborate on the disco...
November 11, 2026 | News
China Accepts Lynk Pharmaceuticals’ Zemprocitinib Filing for Rheumatoid Arthritis
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
November 09, 2026 | News
VS Pharmtech Advances Radiotherapy Enhancer VS-101 to Phase 2 in the US
Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anti...
November 09, 2026 | News
Brise Pharmaceuticals and AbbVie Advance Migraine Drug Collaboration Worth Up to $757 Million
Brise Pharmaceuticals Co., Ltd. provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under ...
November 04, 2026 | News
China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year
Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...
November 03, 2026 | Regulatory
APAC-Originated Obesity Drugs in the Clinic, Beyond Semaglutide
Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...
November 02, 2026 | Analysis
Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...
October 30, 2026 | News
Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
October 29, 2026 | News
EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...
October 28, 2026 | News
Orphan Drug Incentives in 9 APAC Markets, Compared
Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...
October 27, 2026 | Analysis
Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...
October 27, 2026 | News
Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
October 26, 2026 | News
Geneos Launches Global Phase 2 Trial of Personalised Cancer Vaccine to Prevent Liver Cancer Recurrence
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), a...
October 23, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
